e increases in net profits for the quarter and six month
periods were less than the overall sales increase for the period due to
several reasons, which included higher sales of thermal barriers in the
DataTrace line, higher sales of chemical indicator products in the Raven
line and a higher contribution to the sales increases over the first six
months of the fiscal year from sales in international markets. In addition
to these gross margin issues, Administrative costs and Research and
Development cost increases also expanded at a rate greater than the
increase in net sales for both the current three and six month periods of
this fiscal year.
During the first six months of fiscal 2009, the Company repurchased
3,115 shares of our common stock under a previously announced buyback plan
for approximately $67,000. In addition, the Company has a remaining
commitment of approximately $235,000 for capital equipment to automate
certain manufacturing processes for its Raven line of biological indicators
at September 30, 2008. This equipment was delivered in early October of
this year. Once testing and implementation of this equipment is completed
later in the third quarter of fiscal 2009, we do expect to realize
improvements in both our manufacturing costs and delivery times for the
affected products.
As discussed in its dividend announcement today, since establishing the
regular quarterly dividend in November of 2003, the Board has maintained a
policy of reviewing the Company's dividend annually at its regular November
meeting. While the Board believes that the Company has the capacity to
raise the dividend at this time, they have chosen to maintain the dividend
at the current rate of $.10 per share of common stock and exercise caution
with the Company's cash assets given the current disruptions in the credit
markets and the Company's desire to further its growth through acquisitions
which may utilize a large portion of those assets in the future.
Mesa La
'/>"/>
SOURCE Mesa Laboratories, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine news :1.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites2.
Haemacure Reports Third Quarter 2007 Results3.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion4.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best5.
MDS Reports Third Quarter 2007 Results6.
Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 20067.
AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System8.
NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results9.
Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance10.
ReBuilder Medical Technologies, Inc. Reports International Sales Expansion11.
AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.